Research programme: cardiovascular disease diagnostic agents - Kereos/Lantheus Medical Imaging

Drug Profile

Research programme: cardiovascular disease diagnostic agents - Kereos/Lantheus Medical Imaging

Alternative Names: KI-0002

Latest Information Update: 31 May 2010

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Kereos
  • Developer Kereos; Lantheus Medical Imaging
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Cardiovascular disorders

Most Recent Events

  • 31 May 2010 Preclinical development of KI 0002 as an MRI agent for use in the assessment of CVD is ongoing in the US
  • 08 Jan 2008 Bristol-Myers Squibb Medical Imaging has been acquired by Avista Capital Partners, and is now known as Lantheus Medical Imaging
  • 29 May 2007 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top